Karyopharm Therapeutics Files Chapter 11 Bankruptcy on November 2, 2026

The Quick Take

• Karyopharm Therapeutics and subsidiary KPT Texas LLC filed Chapter 11 on November 2
• The biotech company was the developer of selinexor, a cancer treatment marketed as Xpovio
• Chapter 11 reflects inability to sustain operations amid declining revenues and high debt
• Biotech sector faces ongoing valuation reset as late-stage single-asset companies struggle

Karyopharm Therapeutics and its subsidiary KPT Texas LLC filed voluntary Chapter 11 bankruptcy petitions on November 2, 2026, marking the end of an independent path for the developer of selinexor, an XPO1 inhibitor marketed as Xpovio for the treatment of multiple myeloma and other blood cancers. The bankruptcy filing represents a failure to convert an FDA-approved drug into a commercially viable standalone business — a pattern that has become increasingly common in the biotech sector as payers and hospitals push back on premium pricing for drugs that treat small patient populations with alternatives already available. Karyopharm had been burning cash for multiple consecutive quarters without achieving profitability.

The Karyopharm bankruptcy is a cautionary signal for single-asset biotech investors and illustrates the fundamental challenge of commercialising specialty oncology drugs without deep-pocketed pharma partnership or acquisition by a larger company. For the broader biotech sector, the event adds to a series of late-stage company failures and restructurings that have put downward pressure on small-cap and micro-cap biotech valuations since 2022. Investors in XPO1 pathway research and selinexor-adjacent pipeline programmes at other biotechs — including AbbVie and Takeda, which have explored combinations — may need to evaluate whether Karyopharm's assets become available through the Chapter 11 process.

Investors should monitor the Chapter 11 reorganisation plan and whether a stalking horse bidder emerges for Karyopharm's core intellectual property, including the selinexor patent estate and clinical data. The key variable is whether a larger oncology company believes there is pipeline value in the XPO1 inhibitor class that Karyopharm could not commercialise independently. A distressed-asset acquisition at a fraction of historical equity valuations would be the most likely resolution path. The event also reinforces the market's preference for biotechs with diversified pipelines and larger-partner co-development agreements rather than single-molecule commercial strategies.

Synthesized from 1 source.